Minimal clinically important difference for pain on the VAS scale and the relation to quality of life in women with endometriosis

Karin Wickström, Wickström K, Edelstam G, Greta Edelstam
Sexual & reproductive healthcare : official journal of the Swedish Association of Midwives · 2017 · vol. 13 , pp. 35–40 · doi:10.1016/j.srhc.2017.05.004 · PMID:28844356 · W2620116379
article OA: closed CC0 ⤵ 15 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study determined the minimal clinically important difference for pain on the VAS scale and its relationship to quality of life in women with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectivesThe minimal important difference can be helpful in interpreting data from clinical trials. The objective of the study was to calculate the minimal important difference for improvement on the VAS scale for women with endometriosis.Study designA prospective study was conducted to evaluate the effect of pertubation with lignocaine on dysmenorrhea and quality of life in women with endometriosis. Data collected in the trial were used for additional analyses in the present descriptive study. Eligible women (n=37) had endometriosis with pain>VAS 50mm (visual analogue scale).Main outcome measuresIn a questionnaire, women evaluated their maximum pain on the VAS- scale during every menstrual period before and after treatment. They also estimated the changes in overall pain level by answering the response categories "much better", "somewhat better", "about the same", "somewhat worse" or "much worse". The women were grouped according to their own estimation of change in pain intensity after four months. The minimal important differences for change on the VAS scale correlate to the mean change for women who felt "somewhat better" (n=18) excluding those who were pain free (n=2).ResultsThe minimal important difference for improvement on the VAS scale was found to be -39mm and/or -49%.ConclusionIf the patients have a pain level of at least 50mm on VAS scale at inclusion, the cut off for success in clinical trials is suggested to be defined as an either >40mm or a >50% decrease on VAS scale. Trial registry ClinicalTrials.gov Identifier: NCT01329796.

My notes (saved in your browser only)

Condition tags

dysmenorrheaendometriosischronic_pelvic_pain

MeSH descriptors

Endometriosis Minimal Clinically Important Difference Pain Measurement Pelvic Pain Quality of Life Adult Anesthetics, Local Anesthetics, Local Dysmenorrhea Dysmenorrhea Dysmenorrhea Endometriosis Female Humans Lidocaine Lidocaine Pelvic Pain Pelvic Pain Prospective Studies Surveys and Questionnaires

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (34)

Cited by (16)

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:19.560968+00:00
License: CC0 · commercial use OK